Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial
Authors' conclusion
The use of testosterone supplementation in transgender women seems feasible and safe in the short term. Although dosing requires personalized titration, stable testosterone levels can be established. A blinded, placebo-controlled, randomized clinical trial is needed to study the clinical benefit.
Study context
- Population
- Transgender women who underwent gonadectomy
- Participants
- 12 women
- Outcome
- Feasibility of dosing testosterone to the cisgender female physiological range (serum testosterone 1.5–2.5 nmol/L)
Methodological detailsopen-label, dose-titration phase
- Open-label
- Dose-titration phase
Main finding
As reported in the abstract
Dose required to reach serum testosterone 1.5-2.5 nmol/L
- Most participants required 0.07 mL (277 μg bioavailable testosterone) or 0.09 mL (318 μg bioavailable testosterone)
- Testosterone concentrations remained stable throughout the study on continued dose
Further findings
- Changes in clinical outcomes were in the desired direction
Safety
- Side effects were mild
Original publication
Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial. Eur J Endocrinol. Published 20 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →